For multiple sclerosis (MS), it has been reported that baseline serum NfL (sNfL) is a predictor of long-term brain atrophy, development of new T2 lesions, T2 lesion volume, gadolinium (Gd+) lesions, and increased likelihood of progression from radiologically isolated syndromes or clinically isolated syndromes to clinically definite MS (10, 11). Here, NEFL is linked to myeloid sarcoma.